Small Molecules
20 February 2014
OrthoTrophix Initiated Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis and Closed Series A Financing20 February 2014
Vitae Pharmaceuticals Earns $14 Million Milestone Payment from Boehringer Ingelheim in Alzheimer’s Collaboration20 February 2014
VentiRx Pharmaceuticals Presents Phase 1 Data on VTX-2337 at 2014 Multidisciplinary Head and Neck Cancer Symposia20 February 2014
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD20 February 2014
Onconova Announces Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)20 February 2014
Bayer Initiates Phase III Trial of Regorafenib in Patients with Colorectal Cancer after Resection of Liver Metastases19 February 2014
Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients19 February 2014
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma19 February 2014
Chelsea Therapeutics Announces FDA Accelerated Approval of NORTHERA™ (Droxidopa) for the Treatment of Symptomatic NOH18 February 2014
New drug candidate from Vivolux starves cancer cells – clinical study due to begin shortly18 February 2014
Prana Meets Primary Endpoint in Phase 2 REACH2HD Clinical Study of PBT2 for Treating Huntington Disease17 February 2014
Neurovive Pharmaceutical: NeuroVive Treats Final Patient in European Phase III Trial on CicloMulsion17 February 2014
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention17 February 2014
Forest Laboratories to Discontinue NAMENDA® Tablets, Focus on Once-Daily NAMENDA XR®17 February 2014
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis14 February 2014
Dermira Announces Development and Corporate Progress13 February 2014
Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema13 February 2014
Teva Announces Full FDA Approval of SYNRIBO® (Omacetaxine Mepesuccinate) for Injection12 February 2014
Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure12 February 2014
Positive data from the first part of the PLIANT studyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports